Navigation Links
Novartis Reports Omalizumab Significantly Improved Chronic Idiopathic Urticaria Symptoms in Patients Who Failed Standard Therapy
Date:2/24/2013

any Xolair injection. Anaphylaxis has occurred after the first Xolair injection or after many Xolair injections.

A patient's healthcare provider should watch the patient for some time in the office for signs or symptoms of anaphylaxis after injecting Xolair. If patients have signs or symptoms of anaphylaxis, they must tell their healthcare provider right away.

Patients must not receive Xolair if they have ever had an allergic reaction to a Xolair injection. Patients should not use Xolair if they are allergic to any of its ingredients.

In clinical studies, a variety of cancer types, including breast, skin, prostate, and parotid (a type of salivary gland), were reported in more patients who received Xolair than in patients who did not receive Xolair.

Xolair is not a rescue medicine and should not be used to treat sudden asthma attacks.

Xolair is not a substitute for the medicines patients are already taking. Patients must not change or stop taking any of their other asthma medicines unless their doctor tells them to do so.

Some patients on Xolair may have an abnormal increase in eosinophils (a type of white blood cell) in the blood or tissues, sometimes causing an inflammation of blood vessels which can lead to rash, worsening of respiratory symptoms, heart trouble, and/or nerve pain and weakness.

Joint inflammation or pain, rash, fever, and swollen lymph nodes have been seen in some patients taking Xolair after the first or subsequent injections. Patients should talk to their doctor if they have experienced any of these signs and symptoms.

In allergic asthma studies, the most commonly seen side effects occurring more frequently in patients receiving Xolair than in patients who received placebo (an injection with no active medicine) were joint pain, pain (general), leg pain, tiredness (fatigue), dizziness, fracture, arm pain, itching, inflammation of the skin, and earache.

In allergic asthma studies
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Novartis Pharma Logistics, Inc. voluntarily recalling in Jamaica select lots of certain over-the-counter products due to bottle closure defect
2. Novartis Pharma Logistics, Inc. voluntarily recalling in Trinidad & Tobago select lots of certain over-the-counter products due to bottle closure defect
3. Novartis Pharma Logistics, Inc. voluntarily recalling in Curacao select lots of certain over-the-counter products due to bottle closure defect
4. Novartis Pharma Logistics, Inc. voluntarily recalling in Aruba select lots of certain over-the-counter products due to bottle closure defect
5. Novartis Pharma Logistics, Inc. voluntarily recalling in Barbados select lots of certain over-the-counter products due to bottle closure defect
6. Continued Uptake of Novartis/Incytes Jakafi Will Be the Greatest Driver of Growth in the Myelofibrosis Therapy Market
7. Novartis highlights key data in patients with hematologic diseases and breast cancer with more than 140 abstracts at ASH and SABCS
8. Thesan Pharmaceuticals offentliggør første runde af venturefinansieringen ledt af Novo Ventures og Novartis Venture Funds i fællesskab
9. Thesan Pharmaceuticals annuncia un finanziamento di serie A co-gestito da Novo Ventures e Novartis Venture Funds
10. Thesan Pharmaceuticals gibt Serie-A-Finanzierung unter gemeinsamer Führung von Novo Ventures und Novartis Venture Funds bekannt
11. Thesan Pharmaceuticals Announces Series A Funding Co-Led By Novo Ventures And Novartis Venture Funds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... Future Prospects for Companies in Antihistamines, Corticosteroids, ... - new study showing you trends, partnerships, and ... allergic rhinitis drugs heading? What are the commercial prospects ... you potential revenues and other trends to 2025, discussing ... report provides 273 tables, charts, and graphs. Discover the ...
(Date:9/4/2015)... , Sep. 04, 2015 ... of the "Investigation Report on China,s Sodium Ibandronate Market, ... and used in the clinic under the trade name of ... Austria in 1996, sodium ibandronate was approved by ... treatment of osteoporosis under the trade name of Boniva. However, ...
(Date:9/4/2015)... September 4, 2015 Hutchison ... that Hutchison MediPharma Limited ("HMP"), its drug R&D ... second proof-of-concept ("POC") trial of fruquintinib in patients ... in China .  The top-line ... meeting the primary efficacy endpoint of progression free ...
Breaking Medicine Technology:Allergic Rhinitis Drugs Market Forecast 2015-2025 2Allergic Rhinitis Drugs Market Forecast 2015-2025 3Allergic Rhinitis Drugs Market Forecast 2015-2025 4Allergic Rhinitis Drugs Market Forecast 2015-2025 5Allergic Rhinitis Drugs Market Forecast 2015-2025 6Allergic Rhinitis Drugs Market Forecast 2015-2025 7Investigation Report on China's Sodium Ibandronate Market 2010-2019 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 2Second Proof-of-concept Trial of Fruquintinib Achieves its Primary Endpoint 3
... Late Stage Clinical Therapeutic Cancer... -- TUEBINGEN, Germany, September 21, 2010 ... ... ... ,; var first_result; // Results are keyed by longUrl, so we need to grab the first one. ...
... Inc., today announced that it reported positive preclinical ... Association for the Study of Diabetes (EASD).  CCX140, ... the chemokine receptor CCR2, improved metabolic function while ... in an animal model, and was well tolerated ...
Cached Medicine Technology:immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 2immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 3immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 4immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 5immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 6immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 7immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 8immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 9immatics Raises EUR54 Million to Advance its Late Stage Clinical Therapeutic Cancer Vaccine Portfolio 10ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 2ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 3ChemoCentryx Reports Positive Results and Completion of Phase I Clinical Studies of Novel CCR2 Antagonist, CCX140, at the European Association for the Study of Diabetes (EASD) 4
(Date:9/4/2015)... Los Angeles, CA (PRWEB) , ... September 04, 2015 , ... ... new material has been developed that changes color when subjected to an impact force ... article notes, could be implemented in helmets or other sporting equipment so that coaches ...
(Date:9/4/2015)... ... September 04, 2015 , ... The Schmidt National Law Group ... La Paz. , Schmidt National Law Group, a leading firm in mass-tort litigation, ... against Bayer Corp., Bayer Essure, Inc., and other Bayer affiliates for injuries alleged to ...
(Date:9/4/2015)... ... September 04, 2015 , ... Inmar announced ... joint meeting of its Product, Quality and Manufacturers, Dietary Supplements and Supply Chain ... evolving in the consumer goods industry, it can be difficult for companies to ...
(Date:9/4/2015)... ... 2015 , ... “Getting away from the daily stressors and distractions of life ... their ‘couple-ness,’” says Jean Claude Wietzel, general manager at Four Seasons Resort Maui ... only Forbes Five Star resort and Travel + Leisure’s No. 1 Hotel in Hawaii, ...
(Date:9/4/2015)... ... 2015 , ... The conference program for the upcoming Integrative ... 2015 at the Diplomat Resort & Spa has been announced and is available ... the top of their field and will be presenting sessions such as What ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Schmidt National Law Group Files First Bayer Essure® Lawsuit in California 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 2Health News:Inmar Experts To Address OTC Manufacturers’ Session on Hazardous Waste and Handling at CHPA Meeting 3Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 2Health News:Couples Season at Four Seasons Resort Maui Begins This Week With Best Hotel Rates of the Year through November 3Health News:Integrative Healthcare Symposium Focus On: The Microbiome Conference Program Announced 2
... Wash., Feb. 5 The number of Washington retailers illegally ... a new report. The annual rate of illegal sales was ... in 2007 and five percent in 2006. The state ... other state and local agencies to expand the effort to ...
... A Su Salud revealed high incidence of diabetes, osteoporosis, ... million in free and low cost medical services in ... -- CVS/pharmacy, the nation,s leading retail pharmacy, ... (To Your Health) health fairs, providing free health screenings ...
... Researchers from The University of Texas M. D. Anderson ... vessel formation, and vascular endothelial growth factor expression are ... ovarian tumors. This data was presented in a poster ... Annual Meeting on Women,s Cancer. , Sex cord-stromal ...
... Stephens Media LLC of,Las Vegas, Nevada entered ... to deliver Surgery Benefit Management to their health ... care and,personal savings through Healthplace America,s revolutionary surgery ... the Healthplace,Surgery Benefit(TM) is the first -- and ...
... company layoffs, job prospects for rehabilitation therapists ... is projected to increase demand for physical ... assistants up to 27 percent.KENNETT SQUARE, Pa., ... therapy industry continue to experience low rates ...
... Rice University,s Shepherd School of Music will bring together ... in human cognition and behavior for the Exploring the ... the dialogue between musicians and scientists, the conference events ... Shepherd School conference aims to be a trendsetter in ...
Cached Medicine News:Health News:More Retailers Selling Tobacco to Minors 2Health News:More Retailers Selling Tobacco to Minors 3Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 2Health News:CVS/pharmacy Launches 2009 'A Su Salud' Health Fairs Providing Free Health Screenings to the Community 3Health News:Angiogenesis linked to poor survival in patients with rare type of ovarian cancer 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 2Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 3Health News:Stephens Media LLC Partners With Healthplace America to Enhance Employee Healthcare Benefits With Quality and Savings for Surgery 4Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 2Health News:Recession-Proof Your Career: High Job Growth Expected for Rehab Therapists 3Health News:Rice U. conference to explore music's role in human cognition and behavior 2Health News:Rice U. conference to explore music's role in human cognition and behavior 3
... EXOGEN 2000+ device provides a non-invasive ... or the acceleration of fresh fracture ... for 20 minutes daily, or as ... physician determines your fracture to be ...
... growth stimulator is a useful adjunct for the ... or when patient compliance may be a concern. ... are assured of therapeutic treatment directly at the ... to 6 months. , ,The OsteoGen bone growth ...
... Interference Screw has unique, double-helix ... while limiting veering and divergence. ... abrasion where it is most ... thread enables screws to be ...
Cannulated Interference Screws...
Medicine Products: